TESARO (TSRO) PT Lowered to $48.00
TESARO (NASDAQ:TSRO) had its price target lowered by Royal Bank of Canada to $48.00 in a report published on Wednesday, The Fly reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research cut TESARO from a hold rating to a sell rating in a research report on Thursday, January 11th. Cann restated a buy rating and set a $122.00 target price (down from $199.00) on shares of TESARO in a research report on Tuesday. HC Wainwright restated a buy rating and set a $158.00 target price on shares of TESARO in a research report on Monday, November 20th. Cowen dropped their target price on TESARO from $125.00 to $80.00 and set a market perform rating on the stock in a research report on Tuesday, January 2nd. Finally, SunTrust Banks restated a buy rating and set a $160.00 target price on shares of TESARO in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $133.39.
Shares of TESARO (TSRO) opened at $57.68 on Wednesday. The firm has a market capitalization of $3,240.00, a PE ratio of -6.28 and a beta of 1.40. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO has a 12-month low of $52.20 and a 12-month high of $184.00.
In related news, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the sale, the senior vice president now directly owns 8,101 shares in the company, valued at approximately $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 40.50% of the company’s stock.
A number of hedge funds have recently bought and sold shares of TSRO. TimesSquare Capital Management LLC boosted its holdings in TESARO by 226.1% in the 4th quarter. TimesSquare Capital Management LLC now owns 856,600 shares of the biopharmaceutical company’s stock worth $70,986,000 after buying an additional 593,924 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in TESARO by 482.1% in the 4th quarter. Renaissance Technologies LLC now owns 357,400 shares of the biopharmaceutical company’s stock worth $29,618,000 after buying an additional 296,000 shares during the last quarter. Pictet Asset Management Ltd. lifted its stake in TESARO by 58.1% in the 3rd quarter. Pictet Asset Management Ltd. now owns 630,904 shares of the biopharmaceutical company’s stock worth $81,450,000 after purchasing an additional 231,799 shares in the last quarter. BlackRock Inc. lifted its stake in TESARO by 5.6% in the 4th quarter. BlackRock Inc. now owns 4,067,066 shares of the biopharmaceutical company’s stock worth $337,039,000 after purchasing an additional 213,920 shares in the last quarter. Finally, Element Capital Management LLC purchased a new position in TESARO in the 4th quarter worth approximately $16,302,000.
COPYRIGHT VIOLATION NOTICE: “TESARO (TSRO) PT Lowered to $48.00” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/03/tesaro-tsro-pt-lowered-to-48-00.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.